Malaysia Healthcare, Regulatory and Reimbursement Landscape Report 2016-2020 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “CountryFocus:
Healthcare, Regulatory and Reimbursement Landscape – Malaysia”

report to their offering.

Malaysia’s healthcare market has huge potential for growth. Medical
tourism, easy regulatory guidelines, a lack of strict price regulation
and an increasing elderly population, as well as the fact that Malaysia
is not dependent on imported branded products, will provide the
necessary impetus for its growth.

Its value was an estimated $1.2 billion in 2008 and is projected to
reach approximately $3.7 billion by 2020, at a Compound Annual Growth
Rate (CAGR) of 9.5% (MOPI, 2014). The proportion of Malaysia’s
population aged 65 or above is expected to increase at a CAGR of 4.2%,
from 5.5% in 2013 to 7.0% in 2020 (Department of Statistics, 2013b).
Reforms, such as free outpatient registration for the elderly, will
impose a financial and logistical burden on the healthcare system but
will also act as a driver of growth in the healthcare market.

Medical tourism is another driving factor for Malaysia’s pharmaceutical
and healthcare industry. Its healthcare tourism market increased by 51%
in terms of revenue and 63% in terms of visiting foreign patients,
between 2010 and 2012 (MHTC, press release, April 29, 2013). This growth
has been supported by government policies, such as tax exemption for

Government initiatives that aim at increasing investment in the
pharmaceutical industry, such as Entry Point Projects (EPP) and National
Key Economic Areas, have so far been successful.

Companies such as Chemical Company of Malaysia Pharmaceuticals, Biocon,
Ranbaxy (Malaysia) Sdn Bhd and Kotra Pharma have made either significant
investment or strategic agreements in Malaysia as part of the EPP3,
which aims at increasing generic manufacturing for exports (ETP, 2013a).
The expected patent expiry of drugs such as Abilify (aripiprazole),
Celebrex (celecoxib) and Nexium (esomeprazole) will also drive the

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Overview of the Pharmaceutical and Medical Device Markets

4 Market Access

5 Country Analysis

6 Opportunities and Challenges

7 Appendix

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Managed